In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging factor Xa inhibitors will offer clinical advantages over warfarin, their high prices will likely be the greatest obstacle to patient access. Using tiering and restrictions data from Fingertip Formulary and insight from 50 pharmacy directors, we discuss the key trends in reimbursement of AF therapies, the drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to beat the competition.


Related Reports

Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.

According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details

Formulary Advantages in Immune Biologic Therapies: Health plans’ support for certain drug attributes drive formulary coverage for immune biologic brands

The market for immune biologics has grown increasingly crowded in recent years with the launches of newer brands such as Simponi, Cimzia, and Stelara looking to take share away from longer-marketed pr...

View Details